Form 4: Dyne Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4
Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold 2,434 shares to cover tax obligations related to vesting restricted stock units.
Summary
- On March 7, 2024, Jonathan McNeill, the Chief Business Officer of Dyne Therapeutics, sold 2,434 shares of common stock.
- The sale was executed at a weighted average price of $25.85 per share, with individual transactions ranging from $25.84 to $26.33.
- The sale was to cover tax withholding obligations related to the vesting of restricted stock units granted on November 15, 2023.
- Following the transaction, McNeill beneficially owns 141,184 shares, including 137,058 unvested RSUs.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reports a routine transaction to cover tax obligations.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives.
Stakeholder Impact
- The sale of shares could have a minor impact on shareholders due to the slight dilution of equity.
Key Dates
| Date | Description |
|---|---|
| 11/15/2023 | Date of restricted stock units grant |
| 03/07/2024 | Date of share sale transaction |
| 03/11/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.